January 28, 2021
…approach, which would use antibody-rich infusions, can either reduce disease symptoms or prevent infections after exposure to SARS-CoV-2 Parallel to COVID-19 vaccination efforts, physicians and researchers at UC San Diego Health, with collaborators across the country, are conducting a pair of clinical trials to assess whether convalescent plasma (CP) therapy…
April 17, 2020
Physicians and scientists at UC San Diego Health have launched a pair of serological tests that will look for novel coronavirus antibodies—evidence in persons tested that they have previously been infected by the viral cause of COVID-19, even if they never experienced tell-tale symptoms.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
January 25, 2023
For the first time, researchers at UC San Diego have created an atomic-level computer model of the H1N1 virus that reveals new vulnerabilities, suggesting possible strategies for the design of future vaccines and antivirals against influenza.
September 5, 2016
Biochemists at the University of California San Diego have uncovered patterns in the outer protein coat of group A Streptococcus that could finally lead to a vaccine against this highly infectious bacteria—responsible for more than 500,000 deaths a year, including toxic shock syndrome and necrotizing fasciitis or “flesh-eating disease.”
June 6, 2018
…can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
March 22, 2023
UC San Diego researchers describe why SARS-CoV-2 subvariants spread more rapidly than the original virus strain, and how an early treatment might have made people more susceptible to future infections.
June 21, 2022
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by UC San Diego researchers. In mouse models of colon cancer, the therapy eliminated all tumors and prevented their recurrence.
October 4, 2016
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.
December 7, 2021
UC San Diego researchers identify new strategy to improve efficacy of immunotherapy on resistant liver cancers.
